See other companies on Otta
Valo Health
Platform for drug development and discovery
- 101-200 employees
- Healthcare
- B2B
- Enterprise
- Machine Learning
- SaaS
- 399 Boylston Street Suite 505 Boston, MA 02116 United States
Jump to section
Company mission
To make the drug discovery and development process faster, less expensive, and with a higher probability of success.
-23% employee growth in 12 months
Otta's take
Theo Margolius
COO of Otta
Drug development is a critical component of health care. Reducing costs, improving discovery processes, and accelerating drug development are all critical to success in the drug pipeline. Using human-centric data and ML-anchored computation, Valo Health’s integrated drug development platform, known as Opal, improves outcomes in drug development, by leveraging advanced data analysis.
Drug development entails a variety of steps including molecule discovery, clinical development, and target discovery. With the vast amount of data that is generated, a system like Opal incentivizes investment in outcomes that are more likely to correspond with effective treatments. This reduces the number and expense of clinical trials needed to demonstrate drug effectiveness.
There are a variety of competitors in the data-driven drug discovery field, including insitro, Atomwise, and Exscietia, but this vast market should still offer enough space for Valo Health to grow. In 2021, the company experienced a set-back in the surprise calling off of a merger that would have seen it go public, but despite this has continued to operate well and advance towards its goal of transforming the drug development process.
Benefits
- Pet Insurance
- 401K
- Fitness Reimbursement
- Flexible Time-off
- Commuter Reimbursement
- Medical, Dental, and Vision Insurance
- Corporate Engagement Opportunities with Local Non-Profit Organizations
Company values
- Put Patients First
- Succeed As A Team
- There Is No Failure
- Think The Best Of One Another
- Time Is Our Only Limitation
- Take Collective Ownership
Funding (last 2 of 4 rounds)
Mar 2021
$110m
SERIES B
Jan 2021
$190m
SERIES B
$450m
Total funding
This company has top investors
Founders
David Berry
(CEO)David has served as General Partner at Flagship Pioneering, having founded over 25 companies including Indigo Agriculture, Seres Therapeutics, Eleven Biotherapeutics and T2 Biosystems. David was elected as a Young Global Leader by the World Economic Forum and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department.